- Raised $7.1M funding round, Oct 2010
- Raised $2.5M grant, May 2019
- Raised $2.2M grant, Jun 2016
About
Cell Cure Neurosciences is a biotechnology company developing cell therapies based on the use of human embryonic stem cells for the treatment of retinal and neural degenerative diseases. The company uses these powerful stem cells to manufacture the retinal pigment epithelial (RPE) cell.
Cell Cure’s first product in development, OpRegen, contains hESC-derived RPE cells to treat age-related macular degeneration (AMD). OpRegen is being developed as a frontline therapy for the dry form of AMD, which affects approximately 90% of AMD patients.
Cell Cure is currently conducting a phase 1/2 clinical trial of OpRegen to treat the larger market of dry AMD, for which there is currently no FDA-approved therapeutic. The company has recently completed construction of a cGMP manufacturing facility for the production of OpRegen and other cell therapy products.
Cell Cure Neurosciences is a fully owned subsidiary of California-based Lineage Cell Therapeutics, formerly BioTime.
Funding history · 9 rounds · $21.8M total
Q&A
- What is CellCure Neurosciences' primary focus?
- CellCure Neurosciences is a biotechnology company focused on developing cell therapies using human embryonic stem cells for treating retinal and neural degenerative diseases.
- What is CellCure Neurosciences' lead product in development?
- CellCure Neurosciences' lead product is OpRegen, which contains hESC-derived RPE cells designed to treat age-related macular degeneration (AMD), specifically the dry form.
- What is the current clinical trial status of OpRegen?
- CellCure Neurosciences is currently conducting a phase 1/2 clinical trial for OpRegen to treat dry AMD.
- When was CellCure Neurosciences founded?
- CellCure Neurosciences was founded in November 2005.
- How many employees does CellCure Neurosciences have?
- CellCure Neurosciences has 11-50 employees.
- What is CellCure Neurosciences' total funding raised to date?
- CellCure Neurosciences has raised a total of $21,790,000.
- Who is the parent company of CellCure Neurosciences?
- CellCure Neurosciences is a fully owned subsidiary of California-based Lineage Cell Therapeutics, formerly known as BioTime.
- When did CellCure Neurosciences receive its most recent grant?
- In May 2019, CellCure Neurosciences received a grant of $2,500,000 from the Israel Innovation Authority.
- Which investors participated in CellCure Neurosciences' October 2010 funding round?
- In October 2010, CellCure Neurosciences received funding from BioTime Inc. and Hadasit Bio-Holdings.
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | lineagecell.com/manufacturing/ |
|---|---|
| linkedin.com/company/10231887 |
Identifiers & details
| Founded | 2005-11 |
|---|---|
| Employees (exact) | 43 |
Radar intelligence
Web history (Wayback)
| Domain | lineagecell.com |
|---|
Certificate / subdomain footprint
| Subdomains | 6 |
|---|